Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation

Lung cancer has been the leading cause of cancer-related deaths in both developed and developing countries, with most primary lung cancers being non-small cell lung carcinomas. Treatment for this condition is sometimes individualized. With developments in modern treatment and phase III clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thai Hoa Thi, Pham, Xuan Dung, Dao, Khanh Linh, Vo, Thanh Toan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299391/
https://www.ncbi.nlm.nih.gov/pubmed/34326746
http://dx.doi.org/10.1159/000516404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299391/
https://www.ncbi.nlm.nih.gov/pubmed/34326746
http://dx.doi.org/10.1159/000516404

Ejemplares similares